An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Trial Profile

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms ONYX-II
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
    • 17 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top